Thomas Bucknum of Biogen Idec Inc.

The Securities and Exchange Commission began investigating one of the company's top executives after he conveniently sold shares 10 days before stocks dropped by 40% after taking Tysabri off the shelves. In February 2005, Bucknum gained $1.9 million through the sale of his shares and was later charged with insider trading. Bucknum resigned in March 2005 and agreed to repay his stock gain plus $1 million in penalties and interest. Bucknum has agreed to pay a $3 million settlement for insider trading. (Jan-13-06) [BOSTON BUSINESS JOURNAL]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no obligation, please click the link below to submit your complaint.